Psychedelic retreat safety: What to know about the booming business

Psychedelic Retreat Industry Grows Despite Safety Concerns and Legal Challenges

As interest in psychedelic drugs surges across the United States, a new industry has emerged to meet consumer demand: psychedelic retreats. These multiday experiences, where participants pay for drug-assisted sessions claiming to promote psychological healing and personal growth, have proliferated globally despite significant legal and safety concerns.

Hundreds of retreat operators worldwide now offer these experiences, though researchers recently highlighted potential risks in a paper published in JAMA Network Open. The study noted that while many retreats implement safety procedures, they still present “potential for physical, psychological, and interpersonal harms.”

The regulatory landscape may soon shift dramatically. President Donald Trump recently signed an executive order directing the Food and Drug Administration to accelerate reviews of psychedelics showing therapeutic potential for conditions like post-traumatic stress disorder. The order also instructs law enforcement agencies to quickly reduce restrictions on any FDA-approved psychedelics.

However, the FDA’s recent rejection of MDMA for PTSD treatment in 2024 due to safety and efficacy concerns demonstrates the complex regulatory hurdles these substances face.

Dr. John Krystal, a Yale School of Medicine psychiatrist following developments in the field, emphasizes that psychedelics should be approached as “a serious medical procedure that carries risks that must be carefully managed.”

Industry insiders argue today’s retreats represent significant safety improvements over previous decades when psychedelic experiences occurred underground with minimal safety protocols. “The sheer visibility of psychedelics has led to more demand for these retreats,” said Brad Burge, a veteran in the psychedelic industry with nearly 20 years of experience across nonprofits, pharmaceutical companies, and retreat operations. “That growing market has allowed retreats to expand their services, hire more medical and coaching staff, and take safety more seriously than we’ve ever seen in the past.”

Despite these advancements, most psychedelic retreats operate in legally precarious territory. Magic mushrooms, ayahuasca, MDMA, and LSD remain illegal under U.S. federal law. Some retreat companies obscure this reality or claim protection under rare legal exemptions for religious organizations that traditionally use psychedelics.

Only a handful of groups have secured such legal status, including the Native American Church, which uses peyote in ceremonial contexts. To circumvent domestic restrictions, many retreats operate in countries with more permissive laws, such as Peru and Brazil, where ayahuasca has been used for centuries by Indigenous cultures.

The lack of industry-wide standards or regulations creates significant consumer safety concerns. “If there is no regulation, what does that mean about the quality of care you’re going to have?” questioned Joshua White, founder of the Fireside Project, which operates a hotline for people experiencing distress during psychedelic experiences. “I certainly fear that there could be a race to the bottom where there is no liability or accountability.”

Amy McGuire, a biomedical ethicist at Baylor College of Medicine and co-author of the JAMA Network Open study, advises potential attendees to thoroughly research their options. “It’s really important that somebody interested in a psychedelic retreat do their research, talk to the organizers or facilitators to get more information about what is being offered and how,” she said.

McGuire and colleagues found wide variations in practices, including retreats offering multiple psychedelic drugs during a single program. While many have health professionals on site, their roles are often poorly defined. In some concerning cases, medical staff take psychedelics alongside participants, potentially compromising their ability to respond to emergencies.

Experts recommend asking critical questions when evaluating retreats: Do staff have proper training and equipment for medical emergencies? Is there a nearby hospital and available transportation? Do facilitators dedicate significant time to helping participants prepare for and process the experience? Review sites like Retreat.guru provide one source for gathering this information.

One of the most concerning findings from the study involves pre-screening practices. More than half the surveyed retreats excluded participants with serious mental illnesses like schizophrenia, which Dr. Krystal notes is crucial since “psychedelic drugs may worsen symptoms of psychotic disorders.” However, all retreats relied on self-disclosure of medical conditions rather than professional screening.

“When you’re really desperate and hoping to access something that you think could help you, there’s an incentive not to be truthful,” McGuire explained, highlighting a significant safety vulnerability.

Nearly 90% of surveyed retreats also require or recommend that participants discontinue certain medications, particularly antidepressants, before psychedelic experiences. These “washout periods” ranged from one day to six weeks, despite medical recommendations that safely tapering off antidepressants typically requires six to twelve weeks under professional supervision.

Dr. Jeffrey Lieberman, a Columbia University psychiatrist, warns that “by going off their medicine they’re at greater risk of recurrence or exacerbation of their symptoms.” While retreat operators cite concerns about dangerous drug interactions, McGuire suggests there may also be business motivations: “There’s a business rationale for wanting people to have the maximum experience when they show up and they’re paying for these retreats.”

As the psychedelic retreat industry continues to expand in this regulatory gray area, consumers face the difficult task of navigating potential benefits against considerable risks without established safety guidelines or oversight.